Surge In Sales Of Cancer Drug And Heart Medicine Prompts Pfizer To Raise 2019 Forecast
An increase in the sale of cancer drug Ibrance as well as a great launch for its new heart medicine Vyndaqel propelled the third quarter profits for Pfizer Inc which beats estimates of analysts after the company announced its earnings on Tuesday. The strong third quarter performance prompted the company, the largest drugmaker of the…








